Novavax stock falls 2.54 percent below its yearly high

Novavax stock was trading at USD 10.55 on Nasdaq on September 23, 2026, down 2.54 percent during the session and 11.86 percent below its 52-week high of USD 11.97. The market value stood at USD 1.735 billion at the same timestamp.

Revenue falls to USD 56.698 million

Novavax reported USD 56.698 million in revenue for Q2 2026, a 76.2 percent decline from the same quarter a year earlier. The company also posted diluted EPS of USD -0.32 for the period.

According to MarketBeat on August 6, 2026, the EPS result exceeded the consensus estimate of USD -0.38 by USD 0.06, while revenue exceeded the USD 52.51 million estimate by USD 4.19 million. The comparison is favorable on expectations but remains difficult against the prior-year revenue base.

EPS beat meets a weaker sales base

The Q2 revenue figure was lower than Novavax's USD 139.514 million in Q1 2026, a sequential decline of 59.4 percent. Net income was negative at USD -53.387 million in Q2, compared with a USD -9.491 million loss in Q1.

Cash and cash equivalents totaled USD 191.458 million on June 30, 2026, down from USD 228.363 million on March 31, 2026. Operating cash flow was negative USD 72.807 million in Q2, making cash usage a key counterweight to the quarterly EPS beat.

Stock remains below USD 11.97

Novavax stock was trading at USD 10.55 on Nasdaq at 2:44 p.m. ET on September 23, 2026. The intraday range was USD 10.51 to USD 10.95, while the 52-week range extended from USD 6.20 to USD 11.97.